FinanceNews

Indoco Remedies posts Rs 333 crore revenue in Q3 of FY 20-21

Revenue from international business has registered a robust growth of 73 per cent

During the third quarter of FY 2020-21, Indoco Remedies revenue grew by 17.6 per cent at Rs 333.3 crores, as against Rs 283.4 crores, same quarter last year. EBIDTA to net sales for the quarter is 18 per cent at Rs 60 crores, compared to 12.4 per cent at Rs 35.1 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 7.5 per cent at Rs 25.1 crores, compared to 3.3 per cent at Rs 9.3 crores, the same quarter last year. 

For the nine months ended December 2 quarter, the company’s revenue grew by 13 per cent at Rs 922.6 crores, as against Rs 816.2 crores for the same period last year. EBIDTA to net sales is 18.3 per cent at Rs 169.0 crores, compared to 11 per cent at Rs 90 crores, the same period last year. The Profit After Tax to net sales is 7.3 per cent at Rs 67.5 crores, compared to 2.3 per cent at Rs 18.8 crores, the same period last year. 

Commenting on the third quarter FY21 results, Aditi Panandikar, MD, Indoco Remedies, said, “While the revenue from international business has registered a robust growth of 73 per cent, we are yet to see revival in the domestic business. The uptrend in EBIDTA has continued in the third quarter at 18 per cent of net sales, which is highly encouraging.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close